Neil Palmer is Senior Strategic Adviser at PDCI Market Access Inc (PDCI), Canada’s leading pricing and reimbursement consultancy that he founded as Palmer D’Angelo Consulting Inc (PDCI) in 1996. Neil’s current role at PDCI is to provide strategic advice and expertise to PDCI’s clients on important pricing and market access matters. Neil has more that 30 years of pharmaceutical pricing and market access experience and formerly held the titles of Founder, President and Principal Consultant at PDCI.
Neil is also Adjunct Assistant Professor at the University of Southern California School of Pharmacy graduate program in Health Care Decision Analysis where he lectures on health technology assessment, pricing and market access from a global perspective.
From 2006 to 2009, PDCI was a subsidiary of RTI Health Solutions of RTP North Carolina where Neil served as global vice president for pricing and reimbursement before re-acquiring the Canadian operations in 2009.
Prior to PDCI, Neil worked with the Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization.
After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. He has written extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.
Agenda: Day 1 Oct 5, 2020
Afternoon Keynote: INTERNATIONAL REFERENCE PRICING (IRP)
An Overview and Outlook for IRP in North America
IRP is a frequently tossed-around term used in reference to controlling rising drug prices in both Canada and the US. Leverage an in-depth understanding of the history and future consequences for your brands/products. Gain critical insights including:
- Incorporating IRP, the absence of price transparency and role of confidential agreements & patient access schemes
- Informing yourself via a case study how the new basket of 11 reference countries is intended to lower Canadian drug prices to OECD median
- Evaluating the proposed US IRP regulatory proposals and their potential for implementation in current political environment
Assess the impact of IRP on your upcoming launch sequencing & patient access
Agenda: Day 2 Oct 6, 2020